Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

April 2016 - FRMC

04/13/2016
Multiple Myleoma (MM) is a malignant cancer caused by the abnormal accumulation of the plasma cells derived from B cells in the bone marrow, leading to eventual marrow failure and skeletal destruction through bone metastases.1 The American...
Multiple Myleoma (MM) is a malignant cancer caused by the abnormal accumulation of the plasma cells derived from B cells in the bone marrow, leading to eventual marrow failure and skeletal destruction through bone metastases.1 The American...
Multiple Myleoma (MM) is a...
04/13/2016
First Report Managed Care
04/13/2016

Dean Celia

Dean Celia
Industry titans want to exert their heft to alter employer-sponsored health care. Do they have what it takes, and how is managed care responding?
Industry titans want to exert their heft to alter employer-sponsored health care. Do they have what it takes, and how is managed care responding?
Industry titans want to exert...
04/13/2016
First Report Managed Care
04/13/2016

Paul Nicolaus

Paul Nicolaus
As dementia saps the health and resources of an aging population and their family members, university programs are fighting back with innovative solutions.
As dementia saps the health and resources of an aging population and their family members, university programs are fighting back with innovative solutions.
As dementia saps the health and...
04/13/2016
First Report Managed Care
Department
04/12/2016
The FDA has approved Inflectra (infliximab-dyyb, Celltrion Inc) for the treatment of multiple conditions, including rheumatoid arthritis and inflammatory bowel disease. This is the second biosimilar to be approved in the US.
The FDA has approved Inflectra (infliximab-dyyb, Celltrion Inc) for the treatment of multiple conditions, including rheumatoid arthritis and inflammatory bowel disease. This is the second biosimilar to be approved in the US.
The FDA has approved...
04/12/2016
First Report Managed Care
Department
04/12/2016
In response to California’s passage of the “aid in-dying” law, Valeant Pharmaceuticals has doubled the price of Seconal Sodium (secobarbital) to more than $3000.
In response to California’s passage of the “aid in-dying” law, Valeant Pharmaceuticals has doubled the price of Seconal Sodium (secobarbital) to more than $3000.
In response to California’s...
04/12/2016
First Report Managed Care

Department

News Connection
04/13/2016
Primary clinical reviewers from the FDA discuss the changing treatment models for individuals living with the disease.
Primary clinical reviewers from the FDA discuss the changing treatment models for individuals living with the disease.
Primary clinical reviewers from...
04/13/2016
First Report Managed Care
News Connection
04/12/2016
In an expansion of the YMCA’s diabetes prevention program, Medicare will pay for services for individuals at high risk of developing the disease. 
In an expansion of the YMCA’s diabetes prevention program, Medicare will pay for services for individuals at high risk of developing the disease. 
In an expansion of the YMCA’s...
04/12/2016
First Report Managed Care
News Connection
04/12/2016
Coordinated care and a long-term care plan may help reduce unnecessary transitions for patients with dementia according to a study published in the Journal of the American Geriatrics Society.
Coordinated care and a long-term care plan may help reduce unnecessary transitions for patients with dementia according to a study published in the Journal of the American Geriatrics Society.
Coordinated care and a long-term...
04/12/2016
First Report Managed Care
News Connection
04/12/2016
CMS will test a new payment model for nursing facilities and practitioners in long-term care settings that is designed to lower Medicare and Medicaid spending by reducing avoidable inpatient hospitalizations.
CMS will test a new payment model for nursing facilities and practitioners in long-term care settings that is designed to lower Medicare and Medicaid spending by reducing avoidable inpatient hospitalizations.
CMS will test a new payment...
04/12/2016
First Report Managed Care
News Connection
04/11/2016
A study investigated the link between the use of selective serotonin reuptake inhibitors and individual risk of arrhythmia, stroke, and myocardial infarction.
A study investigated the link between the use of selective serotonin reuptake inhibitors and individual risk of arrhythmia, stroke, and myocardial infarction.
A study investigated the link...
04/11/2016
First Report Managed Care

Advertisement

Advertisement

Advertisement